The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 340:1368-1369 April 29, 1999 Number 17
NextNext

von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
by Furlan, M.
-Related Article
by Tsai, H.-M.
To the Editor: The study by Furlan et al. (Nov. 26 issue)1 provides evidence of an inhibitor of von Willebrand factor–cleaving protease in the pathogenesis of thrombotic thrombocytopenic purpura but not of the hemolytic–uremic syndrome. In this study, patients were classified as having either syndrome without knowledge of the results of the von Willebrand factor–cleaving protease assay. However, the authors did not describe the criteria by which the diagnosis was made. In addition, some of the distinguishing characteristics, such as disease chronicity and the likelihood of relapse, could only have been determined retrospectively.

It is remarkable that Furlan et al. . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.